Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone

BMC Psychiatry

Table 3 Relationships between genotype and adverse effects

	CYP2D610*	CYP2D62*	CYP2D665*	Statistics	P
Weight change from week 0 to 4, kg	−1.2 ± 3.0	−2.6 ± 2.5	−13.8 ± 23.4	7.514	0.001
Weight change from week 0 to 8, kg	−1.6 ± 3.6	−3.4 ± 2.0	−1.3 ± 3.8	0.798	0.455
BMI change from week 0 to 8	−0.6 ± 1.3	− 1.3 ± 0.8	− 0.5 ± 1.3	0.985	0.380
GLU change from week 0 to 4, mmol/l	− 0.5 ± 1.8	− 0.3 ± 0.4	−0.2 ± 2.8	0.102	0.903
GLU change from week 0 to 8, mmol/l	−0.3 ± 0.8	−0.6 ± 0.3	0.0 ± 1.4	0.596	0.554
TG change from week 0 to 4, mmol/l	0.0 ± 1.0	0.4 ± 1.1	−0.2 ± 0.6	0.994	0.376
TG change from week 0 to 8, mmol/l	−0.1 ± 1.0	−0.7 ± 1.6	−0.3 ± 0.7	1.800	0.175
CHO change from week 0 to 4, mmol/l	−0.3 ± 0.7	−0.1 ± 0.8	−0.6 ± 1.1	0.984	0.379
CHO change from week 0 to 8, mmol/l	−0.2 ± 0.8	−0.2 ± 0.8	−1.0 ± 2.0	2.395	0.100
LDL change from week 0 to 4, mmol/l	− 0.1 ± 0.5	− 0.1 ± 0.8	− 0.2 ± 0.5	0.964	0.387
LDL change from week0 to 8, mmol/l	− 0.1 ± 0.7	−0.1 ± 0.2	−0.5 ± 0.7	2.631	0.081
HDL change from week 0 to 4, mmol/l	−0.1 ± 0.2	−0.1 ± 0.2	−0.2 ± 0.2	1.041	0.359
HDL change from week 0 to 8, mmol/l	0.0 ± 0.2	−0.1 ± 0.2	−0.3 ± 0.5	3.366	0.042
PRL change from week 0 to 4, mmol/l	52.1 ± 62.9	63.4 ± 63.3	72.5 ± 79.8	0.509	0.603
PRL change from week 0 to 8, mmol/l	39.4 ± 53.7	80.0 ± 65.8	95.4 ± 76.1	4.359	0.017
ESRS week 4	8	0	5	5.858	0.037
ESRS week 8	11	1	4	0.930	0.633
BAS week 4	5	1	2	0.897	0.712
BAS week 8	6	1	1	0.493	0.632

Data are presented as mean ± standard deviation. Abbreviations: BAS Barnes Akathisia Scale, BMI Body mass index, CHO Cholesterol, ESRS Extrapyramidal Symptom Rating Scale, GLU Glucose, HDL High-density lipoprotein, LDL Low-density lipoprotein, PRL Prolactin, TG Triglyceride

ISSN: 1471-244X